Company Information
Bicara Therapeutics is based in Cambridge, Massachusetts, USA. The number of employees in Bicara Therapeutics is unknown. Bicara therapeutics is developing a pipeline of bifunctional antibodies that exploit the recent advances in immuno-oncology.Here is how Bicara Therapeutics describes itself: "Bicara enables access to the thriving innovation ecosystem which accelerates our development of therapies for cancer. Synergies between the Bicara teams in Boston and Bengaluru will pioneer breakthrough innovation."
Funding & investors
Bicara Therapeutics has received 2 rounds of venture funding. The total funding amount is around $80M. Last venture funding round was $40M, announced on March, 2021.Similar Companies [beta]
Venture Categories
Active Venture Investors
Venture Competitors
News
Bicara Therapeutics - Blog
- Bicara Therapeutics Presents Data from Dose Escalation Portion of Ongoing Phase 1/1b Trial of Lead Bifunctional Program, BCA101, at the American Society of Clinical Oncology 2022 Annual Meeting
- Bicara Therapeutics to Present Clinical Data from Lead Bifunctional Antibody Program, BCA101, at ASCO 2022 Annual Meeting
- Bicara Therapeutics Initiates Dose Expansion Arm of Phase 1/1b Clinical Study of BCA101 in Disease-Specific Cohorts
- Bicara Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
- Bicara Therapeutics Presents Promising New Preclinical Data for Lead Immunotherapy Program BCA101 at the Society for Immunotherapy of Cancer 2021 Annual Meeting
- Bicara Therapeutics to Present at Upcoming November Investor Conferences
Durable responses achieved in highly refractory patients as monotherapy (one patient with relapsed squamous cell lung cancer) and...The post Bicara Therapeutics Presents Data from Dose Escalation Portion of Ongoing Phase 1/1b Trial of Lead Bifunctional Program, BCA101, at the American Society of Clinical Oncology 2022 Annual Meeting appeared first on Bicara Therapeutics.
CAMBRIDGE, Mass., May 18, 2022 – Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics designed to elicit...The post Bicara Therapeutics to Present Clinical Data from Lead Bifunctional Antibody Program, BCA101, at ASCO 2022 Annual Meeting appeared first on Bicara Therapeutics.
Study will evaluate BCA101 in patients with head and neck squamous cell carcinoma, squamous cell carcinoma of the...The post Bicara Therapeutics Initiates Dose Expansion Arm of Phase 1/1b Clinical Study of BCA101 in Disease-Specific Cohorts appeared first on Bicara Therapeutics.
CAMBRIDGE, Mass., January 6, 2022 – Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics designed to elicit...The post Bicara Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference appeared first on Bicara Therapeutics.
CAMBRIDGE, Mass., November 12, 2021 – Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics designed to elicit a potent...The post Bicara Therapeutics Presents Promising New Preclinical Data for Lead Immunotherapy Program BCA101 at the Society for Immunotherapy of Cancer 2021 Annual Meeting appeared first on Bicara Therapeutics.
CAMBRIDGE, Mass., November 8, 2021 – Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics designed to elicit...The post Bicara Therapeutics to Present at Upcoming November Investor Conferences appeared first on Bicara Therapeutics.
